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In vitro and in vivo studies have shown that cytochrome P450 3A4 (CYP3A4) is involved in the metabolism of oestrogens. There is
evidence that grapefruit, an inhibitor of CYP3A4, increases plasma oestrogen concentrations. Since it is well established that
oestrogen is associated with breast cancer risk, it is plausible that regular intake of grapefruit would increase a woman’s risk of breast
cancer. We investigated the association of grapefruit intake with breast cancer risk in the Hawaii–Los Angeles Multiethnic Cohort
Study, a prospective cohort that includes over 50000 postmenopausal women from five racial/ethnic groups. A total of 1657 incident
breast cancer cases were available for analysis. Grapefruit intake was significantly associated with an increased risk of breast cancer
(relative risk¼1.30, 95% confidence interval 1.06–1.58) for subjects in the highest category of intake, that is, one-quarter grapefruit
or more per day, compared to non-consumers (Ptrend¼0.015). An increased risk of similar magnitude was seen in users of oestrogen
therapy, users of oestrogenþprogestin therapy, and among never users of hormone therapy. Grapefruit intake may increase the risk
of breast cancer among postmenopausal women.
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The inhibitory effect of grapefruit juice on the intestinal
cytochrome P450 3A4 (CYP3A4) system was discovered acciden-
tally in 1989 during a study designed to test the effect of ethanol on
a calcium-channel blocker (Bailey et al, 1989, 1991). Grapefruit
juice was given to subjects to mask the taste of ethanol. Subsequent
investigations found that through the inhibition of the CYP3A4
enzyme system, primarily in the liver and small intestine
(Guengerich, 1999; Veronese et al, 2003), grapefruit juice interacts
with more than 60% of orally administered drugs leading to
elevation of their serum concentrations (Maskalyk, 2002; Bailey
and Dresser, 2004). Consumption of a single glass (six ounces) can
produce the maximal acute pharmacokinetic effect (Edgar et al,
1992; Lundahl et al, 1995, 1997; Dahan and Altman, 2004) with
enhanced oral drug bioavailability occurring up to 24h after juice
consumption (Bailey and Dresser, 2004).
Since 1989, the list of drug interactions with grapefruit juice has
expanded to include oral 17b-oestradiol and progesterone
(Guengerich, 1999; Maskalyk, 2002; Medical Letter, 2005). The
US Food and Drug Administration (FDA) mandated labelling for
hormone products for postmenopausal women now contains
warnings that grapefruit juice may increase plasma concentrations
of oestrogen (US Food and Drug Administration, 2006). Schubert
et al (1994) found that grapefruit juice increased the area under the
curve of oestradiol approximately 20% in ovariectomised women.
Recently, we reported that endogenous oestrogen levels were about
30% higher in postmenopausal women in whom periods had
stopped naturally and who were consuming the equivalent of 1
4
grapefruit or more per day (Monroe et al, 2007).
It is well established that oestrogen is associated with breast
cancer risk (Key et al, 2002). Therefore, if grapefruit intake affects
oestrogen metabolism leading to higher circulating levels, then it is
biologically plausible that regular intake of grapefruit would
increase a woman’s risk of breast cancer. To our knowledge, no
study has yet examined this hypothesis. The present study
investigated the association of grapefruit intake and breast cancer
risk in the Hawaii–Los Angeles Multiethnic Cohort (MEC) Study.
MATERIALS AND METHODS
Study population
The MEC was assembled in 1993–1996 when 96810 adult men and
118441 adult women, aged 45–75 at baseline, completed a 26-
page, self-administered mailed questionnaire that contained a
quantitative food frequency questionnaire (FFQ) and information
on demographic factors, personal behaviours, prior medical
conditions, use of medications, family history of common cancers,
and, for women, reproductive history and use of oral contra-
ceptives and hormone therapy (HT). The study was approved by
the Institutional Review Boards of the University of Hawaii and the
University of Southern California. Further details regarding the
study have been given elsewhere (Kolonel et al, 2000).
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Americans, Japanese Americans, Latinas, Native Hawaiians, and
Caucasians – were included in the study reported here. Also we
only included women who reported that their menstrual periods
had stopped naturally or due to oophorectomy. Women who had
undergone hysterectomy but reported one or more ovaries still
intact were excluded. We also excluded women with missing or
invalid data for weight, height, oestrogen and/or progestin use, age
at menarche, parity, age at first live birth, age at natural
menopause or age at bilateral oophorectomy, physical activity,
smoking status, or education level. We also excluded subjects if
they had been diagnosed with cancer other than non-melanoma
skin cancer before cohort entry. Finally, we excluded subjects if
their intake of calories or its components (fat, protein, and
carbohydrate) from the baseline FFQ fell outside a defined valid
range (Nothlings et al, 2005). As a result, data for 46080
postmenopausal women were available for analysis.
Surveillance
Incident cases of breast cancer in California were identified by
linkage to the Los Angeles County SEER registry and to the State of
California Cancer Registry (CCR). Incident cancers in Hawaii were
identified using the statewide Hawaii SEER registry and the CCR
was used to identify cases who had moved to California. A software
program was used to conduct a probabilistic data linkage using
social security number, name, and date of birth. We had a social
security number on 98.7% of the cohort. Further, we determined
that after an average period of 7 years in the cohort, the out-
migration rate was 3.7% (4.9% for Hawaii participants and 2.5%
for California participants). Although the out-migration rate is
somewhat higher for Hawaii, California is the primary destination
for these migrants, so that most remain under surveillance for
cancer incidence. Mortality was determined by annual linkage to
state death files in California and Hawaii, and periodically to the
National Death Index. Follow-up time began on the date the
respondent completed the baseline questionnaire and, for the
analysis reported here, continued through 31 December 2002.
Subjects were censored at the date of last follow-up, date of death,
or date of diagnosis of cancer, whichever occurred earlier.
Assessment of grapefruit intake from baseline
questionnaire
The methods for dietary assessment have been described in detail
elsewhere (Kolonel et al, 2000). The FFQ asked respondents to
report how often they ate ‘grapefruit or pomelo’ during the past
year and the usual portion size. Usual intake was reported by
marking one of the following eight frequencies: never or hardly
ever; once a month; 2–3 times a month; once a week; 2–3 times a
week; 4–6 times a week; once a day; 2 or more times a day. Portion
sizes for whole grapefruit included 1
4 cup or less, 1
2 grapefruit or 1
2
cup, and 1 cup or more. The average weight of one grapefruit was
estimated to be 240g. Total grapefruit intake was calculated by
multiplying the frequency and portion size and expressed as grams
per day. We were unable to quantify intake of grapefruit juice as it
was combined with orange juice in the FFQ. The performance of
the FFQ in a calibration sub-study has been previously reported
(Stram et al, 2000).
Menopausal hormone therapy use from baseline
questionnaire
Subjects were asked about use of menopausal oestrogen therapy
(ET) and progestin therapy (PT) separately in the baseline
questionnaire. Oestrogenþprogestin therapy (EPT) was calculated
based on the overlap between reported periods of ET and PT use
(Lee et al, 2006). For the present analysis, we used a categorical
variable defined as follows: (1) no HT use; (2) past HT use; (3)
current ET use; and (4) current EPT use.
Statistical analysis
Hazard ratios for breast cancer incidence, referred to in this report
as relative risks (RRs), were estimated using log-linear regression
proportional hazard models stratified on age at recruitment (single
year), year of recruitment (single year), race/ethnicity (African
American, Japanese, US-born Latina, Latina born in Mexico or
other Central or South American country, Native Hawaiian, and
Caucasian), and study centre (Hawaii/California). We examined
grapefruit intake by categories of both absolute intake (none,
o30g, o60g, and X60g) and intake per 1000kcal (none, o15,
o30, and X30g per 1000kcal). The highest category of absolute
intake (X60g) was an average of slightly greater than 1
4 grapefruit
per day or 1
2 every other day. The highest category of intake density
was roughly equivalent. Categories were determined by usual
serving size (as defined above) from the FFQ and the intake
distribution for all subjects. Non-dietary factors considered as
potential confounders included age at menarche (p12, 13–14, and
15þ), age at first live birth (p20, 21–30, and 31þ), parity
(nulliparous, 1 child, 2–3 children, and 4þ children), age at and
type of menopause (natural menopause at age o45, 45–49, 50–54,
and 55þ or oophorectomy at age o45, 45–49, and 50þ),
postmenopausal oestrogen and/or progestin use (as defined
above), weight (continuous) and height (continuous) at recruit-
ment, physical activity (continuous variable for hours per day
engaged in vigorous work and/or strenuous exercise), family
(mother or sister) history of breast cancer (yes/no), education level
attained (p10th grade, high school, some college or vocational
school, and college graduate), and smoking status at baseline
(never, former, and current). Dietary factors considered as
potential confounders included intakes of alcohol, total energy,
saturated fat, total dietary fibre, and soluble and insoluble fibre
fractions. The dietary fibre value used in the present study is that
published in the USDA tables and is the sum of lignin and non-
starch polysaccharides in plant foods (Prosky et al, 1985). The
values for insoluble and soluble fractions were obtained by the
Englyst procedure, which aims to measure plant cell wall non-
starch polysaccharides as the sum of the chemically identified
constituent sugars; the procedure does not measure lignin (Englyst
et al, 1994). Although these two methods of fibre analysis are
highly correlated, they are nevertheless distinct from one another
and may not be combined. The variables included in the final
multivariate model were established risk factors and factors we had
found to influence serum oestrogen levels in our previous study
(Monroe et al, 2007), that is, dietary fibre and soluble fibre intakes.
The underlying time variable in the analysis was time from the date
of cohort enrollment to the date of breast cancer diagnosis, death,
or censoring.
Calculations were performed using the SAS (SAS Institute, Cary,
NC, USA) and STATA (Stata Corporation, College Station, TX,
USA) statistical software packages. Testing for significance was
performed using likelihood ratio methods. All P-values quoted are
two-sided.
RESULTS
A total of 1657 of the women in the defined cohort were diagnosed
with incident breast cancer before 31 December 2002 and are
included in the analysis. Some baseline characteristics of the breast
cancer cases and the total study population are shown in Table 1.
Japanese Americans comprise the largest group with 32% of the
population followed by Caucasians with 26%. Overall, whole
grapefruit was consumed by 50% of the study population with 7%
reporting intake of 1
4 grapefruit or more per day. Grapefruit was
Grapefruit intake and breast cancer
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Americans, 49% of Caucasians, 45% of Latinas, and 35% of
Hawaiian study subjects.
Table 2 shows the risk of breast cancer across category of
grapefruit intake quantified by absolute intake (g) and by intake
density (g per 1000kcal). The first relative risk (RR1) estimate was
adjusted for (stratified on) age at recruitment, year of recruitment,
race/ethnicity, and study centre. Intake of 1
4 grapefruit or more
per day is associated with a 21% increase in breast cancer risk
(RR1¼1.21, 95% confidence interval (CI)¼1.00–1.46, Ptrend¼
0.044); the highest category of grapefruit density (X30g per 1000kcal)
is also associated with increased breast cancer risk (RR1¼1.18,
95% CI¼0.98–1.42, Ptrend¼0.040). Second relative risk (RR2)
estimate was adjusted (stratified) as above, and further adjusted
for weight, height, physical activity, education, age at menarche,
age at first birth, parity, age at and type of menopause, menopausal
oestrogen/progestin use, cigarette smoking, family history of
breast cancer, alcohol, saturated fat, total dietary fibre, and soluble
fibre. With these adjustments, intake of 1
4 grapefruit or more per
day is significantly associated with a 30% increase in breast cancer
risk (RR2¼1.30, 95% CI¼1.06–1.58, Ptrend¼0.015); the highest
category of grapefruit density is likewise associated with a 25%
increase in breast cancer risk (RR2¼1.25, 95% CI¼1.03–1.52,
Ptrend¼0.013). The increase in RR from RR1 to RR2 was due to
adjustment for total dietary fibre and soluble fibre; adjustment for
insoluble and soluble fibre produced almost identical results (data
not shown).
The associations between grapefruit intake and breast cancer
risk by category of HT use are shown in Table 3. The reference
category for all RR estimates is never HT/non-consumers of
grapefruit. Because the results for grapefruit intake density were
similar to results for absolute intake, we present only the latter.
Among never HT users, there is a statistically significant positive
association between the highest category of grapefruit intake
(X60g per day) and breast cancer risk (RR¼1.44, 95% CI¼1.08–
1.93, Ptrend¼0.038). There is no trend among past HT users. For
current ET users, there is an increase in risk of 36% from the
lowest (zero) category of intake to the highest (Ptrend¼0.22); for
current EPT users, breast cancer risk increases 27% from the
lowest to the highest category of grapefruit intake (Ptrendo0.13).
There was a dose–response relationship between grapefruit intake
and breast cancer risk in never HT users and in current ET and
EPT users. Although the trend tests are not significant for current
ET and EPT users, the pattern is the same in the three groups, and
there is no statistical evidence that the magnitudes of the trends
differ.
We examined whether the association of grapefruit intake and
breast cancer risk was modified by body mass index (BMI: weight
in kilograms/(height in metres)
2). Subjects were divided into two
categories: lean/normal weight (BMIo25.0) and overweight/obese
(BMIX25.0). The association between grapefruit intake and breast
cancer risk was not modified by BMI, as shown in Table 4. The
reference category for all RR estimates is BMIo25.0/non-
consumers of whole grapefruit. Among lean/normal weight
subjects, there is a statistically significant increased risk of breast
cancer associated with grapefruit intake. Risk increases 32% from
the lowest (zero) category of intake to the highest (Ptrend¼0.011).
Among overweight/obese subjects, breast cancer risk increases
26% from the lowest to the highest category (RR¼1.46, 95%
CI¼1.10–1.96), although the test for trend is not statistically
significant.
DISCUSSION
To our knowledge, this is the first report of a commonly consumed
food that may increase the risk of breast cancer among
postmenopausal women. Whole grapefruit intake was significantly
Table 1 Baseline characteristics of breast cancer cases and the total
study population
Cases Total population
No. of subjects 1657 46080
Age at cohort entry (in years), mean (s.d.) 62.1 (7.27) 61.5 (7.35)
Body mass index, mean (s.d.) 25.5 (5.20) 25.6 (5.28)
Race/ethnicity
African American 253 8,398
Japanese American 579 14906
Latina 248 8404
Native Hawaiian 144 2608
Caucasian 433 11764
Education
p10th grade 217 7063
High school 487 14183
Some college or vocation school 482 13585
College graduate 471 11249
Age at menarche
p12 834 22138
13–14 642 18151
15+ 181 5791
Age at first live birth
Never 271 5939
p20 343 12046
21–30 888 24923
31+ 155 3172
Parity
Nulliparous 271 5939
1 child 202 5012
2–3 children 750 20537
4+ children 434 14592
Type of and age at (in years) menopause
Natural, o 45 167 5346
Natural, 45–49 392 11177
Natural, 50–54 601 15612
Natural, 55+ 198 4148
Oophorectomy, o 45 152 5395
Oophorectomy, 45–49 92 2898
Oophorectomy, 50+ 55 1504
Postmenopausal HT use
Never 631 20959
Former HT use 259 8436
Current ET use 207 5843
Current EPT use 560 10842
Smoking status
Never smoker 908 25938
Former smoker 535 13811
Current smoker 214 6331
Family history of breast cancer
Yes 271 5005
No 1386 41075
Alcohol intake
None 977 28556
o12g per day (one drink) 466 12876
o24g per day 82 2108
X24g per day 132 2540
Grapefruit intake
None 794 23203
o30g per day 635 16911
o60g per day 95 2692
X60g per day (1
4 grapefruit) 133 3274
EPT¼oestrogen+progestin therapy; ET¼oestrogen therapy; HT¼hormone
therapy.
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30% increase among subjects who consume the equivalent of 1
4
grapefruit or more per day.
To reduce measurement error in dietary assessments, investi-
gators often energy-adjust intakes by calculating densities, that is,
g per 1000kcal of total energy intake. Densities represent the
contribution of a particular nutrient or food group in relation to
overall dietary intake as measured by the FFQ (Willett, 1998).
However, individual food intakes, particularly with respect to
fruits and vegetables, are also commonly examined in terms of
absolute or crude intake (van Gils et al, 2005). The biologic
implication of the two analytic approaches needs careful
consideration when interpreting diet–disease associations (Willett,
1998). We considered this issue in our data and found that both
approaches produced similar results. We present the detailed
results in terms of absolute intake to make them more easily
interpretable.
The measure of grapefruit intake in the present study, based on
intake of the whole fruit, is an underestimation of total intake
owing to a lack of information on grapefruit juice. If one makes the
assumption that grapefruit juice intake is highly correlated with
whole fruit intake, then the magnitude of risk observed in the
Table 3 Relative risks (with 95% confidence intervals) of breast cancer across categories
a of grapefruit intake by HT use
Grapefruit (g per day) 0 40t oo30g X30 to o60g X60g Ptrend
Never HT
No. of cases 298 244 30 59 —
Adjusted RR1 1.00 1.19 (1.00–1.41) 0.87 (0.59–1.27) 1.44 (1.08–1.93) 0.038
Past HT
No. of cases 133 91 17 18 —
Adjusted RR1 1.22 (0.99–1.50) 1.13 (0.88–1.43) 1.44 (0.87–2.37) 1.17 (0.72–1.92) 0.97
Current ET
No. of cases 125 109 19 22 —
Adjusted RR1 1.56 (1.21–2.01) 1.70 (1.29–2.23) 1.85 (1.06–3.25) 2.12 (1.29–3.49) 0.22
Current EPT
No. of cases 238 191 29 34 —
Adjusted RR1 2.01 (1.69–2.40) 2.09 (1.73–2.51) 2.48 (1.72–3.58) 2.55 (1.80–3.63) 0.13
EPT¼oestrogen+progestin therapy; ET¼oestrogen therapy; HT¼hormone therapy; RR1¼first relative risk. RR1 stratified on age at recruitment, year of recruitment, race/
ethnicity, and study centre and adjusted for weight, height, physical activity, education, age at menarche, age at first birth, parity, age at and type of menopause, smoking, family
history of breast cancer, alcohol, total energy, saturated fat (g per 1000kcal), dietary fibre (g per 1000kcal), and soluble fibre (g per 1000kcal).
aCategories for grapefruit intake
are based on total grams for one grapefruit¼240g per day. The highest category therefore represents 1
4 grapefruit every day or 1
2 every other day.
Table 2 Relative risks (with 95% confidence intervals) of breast cancer across categories
a of grapefruit intake
Grapefruit (g per day)
Intake None 40t oo30g X30 to o60g X60g Ptrend
No. of cases 794 635 95 133 —
Adjusted RR1 1.00 1.08 (0.97–1.21) 1.04 (0.83–1.29) 1.21 (1.00–1.46) 0.044
Adjusted RR2 1.00 1.08 (0.97–1.20) 1.07 (0.86–1.34) 1.30 (1.06–1.58) 0.015
Grapefruit (g per 1000kcal per day)
Intake None 40t oo15g X15 to o30g X30g —
No. of cases 794 632 93 138 —
Adjusted RR1 1.00 1.08 (0.97–1.20) 1.12 (0.90–1.40) 1.18 (0.98–1.42) 0.040
Adjusted RR2 1.00 1.07 (0.96–1.19) 1.17 (0.94–1.47) 1.25 (1.03–1.52) 0.013
RR1¼first relative risk; RR2¼second relative risk. RR1 stratified on age at recruitment, year of recruitment, race/ethnicity, and study centre. RR2 stratified as above and adjusted
for weight, height, physical activity, age at menarche, age at first birth, parity, age at and type of menopause, oestrogen and/or progestin use, smoking, education, family history of
breast cancer, alcohol, total energy, saturated fat (g per 1000kcal), dietary fibre (g per 1000kcal), and soluble fibre (g per 1000kcal).
aCategories for grapefruit intake are based
on total grams for 1 grapefruit¼240g per day. The highest category therefore represents 1
4 grapefruit every day or 1
2 every other day.
Table 4 Relative risks (with 95% confidence intervals) of breast cancer across categories
a of grapefruit intake by BMI
Grapefruit (g per day) 0 40t oo30g X30 to o60g X60g Ptrend
BMIo25.0
No. of cases 407 339 55 74
Adjusted RR1 1.00 1.05 (0.90–1.22) 1.14 (0.85–1.52) 1.32 (1.02–1.72) 0.011
BMIX25
No. of cases 387 296 40 59
Adjusted RR1 1.16 (1.00–1.34) 1.30 (1.11–1.52) 1.16 (0.83–1.62) 1.46 (1.10–1.96) 0.113
BMI¼body mass index; RR1¼first relative risk. RR1 stratified on age at recruitment, year of recruitment, race/ethnicity, and study centre and adjusted for oestrogen/progestin
use, physical activity, education, age at menarche, age at first birth, parity, age at and type of menopause, smoking, family history of breast cancer, alcohol, total energy, saturated
fat (g per 1000kcal), dietary fibre (g per 1000kcal), and soluble fibre (g per 1000kcal).
aCategories for grapefruit intake are based on total grams for one grapefruit¼240g per
day. The highest category therefore represents 1
4 grapefruit every day or 1
2 every other day.
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breast cancer owing to total intake not just whole fruit intake.
However, if there is little correlation between whole grapefruit and
grapefruit juice intakes, and if one accepts that grapefruit juice
intake increases breast cancer risk in the same manner as the
whole fruit, then the magnitude of risk observed in the present
study may be an underestimation of the true risk. This requires
further study.
Beginning in the 1980s, it was hypothesised that dietary fibre
may have a beneficial effect on breast cancer incidence by lowering
endogenous oestrogen levels through the partial interruption by
dietary fibre of the enterohepatic recirculation of oestrogens
(Goldin et al, 1982, 1986; Adlercreutz, 1990). While recent
epidemiological evidence supports a role for dietary fibre intake
in relation to lower endogenous hormone levels (Rock et al, 2004;
Prentice et al, 2006), the question remains unsettled. In our study
of endogenous oestrogen levels in postmenopausal women,
oestradiol decreased monotonically from 10.6 to 6.2pgml
 1 from
the lowest to the highest quintile of dietary fibre intake (median
intake of 9.9–21.7g per 1000kcal), whereas soluble fibre, after
adjustment for dietary fibre, was associated with an increase in
oestradiol from 6.8 to 11.5pgml
 1 from the lowest to the highest
quintile of intake (median intake of 2.9–7.1g per 1000kcal)
(Monroe et al, 2007). Taken together, these results suggested that
the component of total dietary fibre not accounted for by soluble
and insoluble fibre was strongly negatively associated with serum
oestradiol while soluble fibre increased oestradiol levels. This is
complex as most plant foods contain a mixture of soluble and
insoluble fibre, as well as other constituents. We hypothesised that
the result for total dietary fibre represented high lignin-containing
foods as lignin is the primary constituent of dietary fibre not
accounted for by soluble and insoluble fibre. Further, there is
evidence that lignin adsorbs oestrogen, more so than other fibre
components (Shultz and Howie, 1986; Arts et al, 1991).
In the present study, the addition of total dietary fibre and
soluble fibre to the statistical model modified the estimate of breast
cancer risk associated with grapefruit intake (RR1 to RR2 in
Table 2). On the basis of our observation that intakes of total
dietary fibre and soluble fibre are significantly associated with
serum oestrogen levels in naturally postmenopausal women, and
the in vitro evidence that certain fibre components, particularly
lignin, have the ability to adsorb oestrogen, the adjustment will
provide a more accurate estimate of breast cancer risk associated
with grapefruit intake.
Consistent with other studies on postmenopausal oestrogen use,
we found an increase in breast cancer risk, particularly among
current EPT users. One aim of our study was to examine the risk of
breast cancer associated with grapefruit intake by subgroup of
menopausal HT use. As endogenous oestrogens are metabolised in
the same manner as exogenous estrogens (US Food and Drug
Administration, 2006), we had hypothesised that grapefruit intake
would increase a woman’s risk of breast cancer, regardless of HT
use. Support for the hypothesis among women taking HT was
provided by the warning in FDA mandated labelling of meno-
pausal HT products that grapefruit juice may increase plasma
concentrations of oestrogens.
The association between grapefruit intake and breast cancer risk
was clearly seen in never HT users, as well as current ET and EPT
users. Interestingly, the RR of breast cancer associated with
consumption of 1
4 grapefruit or more per day compared to non-
consumers was 44% higher among women who had never used
HT, 36% higher in current ET users, and 27% higher among
current EPT users. The risk of breast cancer associated with
consumption of grapefruit was 32% higher among lean/normal
weight women and 26% higher among overweight/obese women.
Taken together, these results for HT and BMI suggest that the risk
of breast cancer associated with grapefruit intake is stronger for
subgroups of women with lower circulating oestrogen levels.
This finding of a reduced effect of grapefruit in women with a
higher BMI is similar to the lower effect of ET on breast cancer risk
in women with a higher BMI (Collaborative Group on Hormonal
Factors in Breast Cancer, 1997; Schairer et al, 2000; Million
Women Study Collaborators, 2003; Beral et al, 2005). The lower RR
associated with ET in heavier women can be explained by the
elevated endogenous oestrogen level in heavier women, and
detailed analysis suggests that the ceiling of effective oestrogen
as regards the breast is achieved by women with a BMI of
approximately 32kgm
 2 (Wu et al, 2007). In the same way,
increased oestrogen levels from grapefruit intake may have less
and less effect as the ‘baseline’ oestrogen levels increase. Because
the ‘baseline’ oestrogen level of women on ET or EPT is greater
than the effective oestrogen ceiling (Wu et al, 2007), the increased
risk from grapefruit intake in these women may be partly a long-
term effect of increased progesterone levels in the premenopausal
period, but this remains to be studied.
Previous studies have reported that the magnitude of interaction
between a drug and grapefruit juice is markedly variable among
individuals (Bailey et al, 1993, 1995; Lown et al, 1997; Bailey and
Dresser, 2004). Subjects with the highest intestinal expression of
CYP3A4 showed the greatest increase in plasma drug concentra-
tion of felodipine after grapefruit juice administration (Lown et al,
1997). Currently, there is no way to predict the potential
interaction; such studies are urgently needed.
In our study of grapefruit intake and serum oestrogen levels, we
observed an approximately 30% increase in oestrone and a 10%
increase in oestradiol levels among women who consumed the
equivalent of 1
4 grapefruit or more per day. In the present study, we
observed a 25–30% increase in breast cancer risk in the highest
category of grapefruit intake. The meta-analysis of the relationship
between levels of endogenous sex hormones and breast cancer risk
in postmenopausal women by the Endogenous Hormones and
Breast Cancer Collaborative Group (Key et al, 2002) found that a
doubling of oestradiol was associated with an RR of breast cancer
of 1.29 (95% CI¼1.15–1.44). These results suggest that we should
have observed a much smaller increase in breast cancer risk in the
present study. Even if one uses the 30% increase in oestrone, then
we should have found about a 12% increase in risk. The reason for
the greater breast cancer risk than would be predicted solely on the
basis of postmenopausal oestrogen levels may have a number of
possible explanations. First, it may be due to chance since the CI in
the present study includes such a value. Second, the estimated 30%
increase in oestrone levels from grapefruit intake may be an
underestimate because of misclassification of true dietary intake
and because it does not include grapefruit juice. Third, grapefruit
may influence oestrogen and progesterone levels in the premeno-
pausal period and the larger effect we see is partly a carry-over
effect. Other explanations are possible; more work is certainly
needed.
It is biologically plausible that grapefruit intake may increase the
risk of breast cancer among postmenopausal women. However, the
results of the present study need to be confirmed in other studies
with more comprehensive measures of grapefruit intake that
include both the whole fruit and grapefruit juice.
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